General Information of Drug (ID: DM1XY5F)

Drug Name
MN-462 Drug Info
Synonyms EF-6265; CPB/TAFIa inhibitor, MediciNova; CPB/TAFIa inhibitor, Meiji Seika Kaisha/MediciNova; Carboxypeptidase B/thrombin-activated fibrinolysis inhibitor, Meiji Seika Kaisha/MediciNova
Indication
Disease Entry ICD 11 Status REF
Thrombosis DB61-GB90 Investigative [1]
Cross-matching ID
TTD Drug ID
DM1XY5F

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Carboxypeptidase B2 (CPB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-126119 DMKHM7O Cerebrovascular ischaemia 8B1Z Phase 1 [2]
UK-396082 DMFYKDX Thrombosis DB61-GB90 Phase 1 [3]
DS-1040 DMXCN37 Ischemic stroke 8B11.5Z Phase 1 [4]
SAR-104772 DMQ9ZY0 Cerebrovascular ischaemia 8B1Z Phase 1 [5]
AZD-9684 DMHA5ME Thrombosis DB61-GB90 Discontinued in Phase 2 [6]
PMID14640538C3 DMR2L6X Discovery agent N.A. Investigative [7]
DL-benzylsuccinic acid DMHI9ZJ Discovery agent N.A. Investigative [8]
PMID19954973C4 DMDYZE5 Discovery agent N.A. Investigative [3]
3-mercapto-2-(piperidin-3-yl)propanoic acid DMPJBNC Discovery agent N.A. Investigative [9]
6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid DMMUE05 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carboxypeptidase B2 (CPB2) TTP18AY CBPB2_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1594).
2 TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6.
3 Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
4 Clinical pipeline report, company report or official report of Daiichi Sankyo.
5 Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009.
6 Clinical pipeline report, company report or official report of AstraZeneca.
7 Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
8 A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
9 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
10 Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5.